Research programme: Alzheimer's disease therapeutics - ENKAM
Alternative Names: FGL-SLatest Information Update: 28 Jul 2018
At a glance
- Originator ENKAM Pharmaceuticals A/S
- Class Antidementias; Peptides
- Mechanism of Action Fibroblast growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Cognition disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in Denmark (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cognition-disorders in Denmark (Parenteral)
- 08 Dec 2011 Preclinical trials in Cognition disorders in Denmark (Parenteral)